Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-05-08 2:22 pm Sale | 13G | UROGEN PHARMA LTD URGN | BlackRock Inc. BLK | 1,669,543 4.6% | -49,761 (-2.89%) | View |
2024-02-22 09:23 am Unchanged | 13D | UROGEN PHARMA LTD URGN | Arkin Moshe | 1,369,315 4.44% | 0 (Unchanged) | View |
2024-02-14 5:01 pm Purchase | 13G | UROGEN PHARMA LTD URGN | RA CAPITAL MANAGEMENT L.P. | 3,083,558 9.99% | 8 (+0.00%) | View |
2024-02-14 4:38 pm Unchanged | 13G | UROGEN PHARMA LTD URGN | GREAT POINT PARTNERS LLC | 2,620,545 8.49% | 0 (Unchanged) | View |
2024-02-14 10:02 am Sale | 13G | UROGEN PHARMA LTD URGN | MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 7.46% | -615,971 (-21.10%) | View |
2024-02-14 10:01 am Sale | 13G | UROGEN PHARMA LTD URGN | Stonepine Capital Management LLC | 0 0% | -1,304,947 (Position Closed) | View |
2024-02-14 07:07 am Purchase | 13G | UROGEN PHARMA LTD URGN | RTW INVESTMENTS LP | 1,726,808 5.6% | 1,726,808 (New Position) | View |
2024-02-02 2:18 pm Purchase | 13G | UROGEN PHARMA LTD URGN | BlackRock Inc. BLK | 1,719,304 5.6% | 1,378,892 (+405.07%) | View |
2023-12-29 4:30 pm Purchase | 13G | UROGEN PHARMA LTD URGN | RA CAPITAL MANAGEMENT L.P. | 3,083,550 9.99% | 3,083,550 (New Position) | View |
2023-09-15 1:39 pm Purchase | 13G | UROGEN PHARMA LTD URGN | GREAT POINT PARTNERS LLC | 2,620,545 8.51% | 2,620,545 (New Position) | View |
2023-08-04 08:56 am Purchase | 13D | UROGEN PHARMA LTD URGN | Monograph Capital Holdings Advisors LLC | 1,662,327 5.4% | 1,662,327 (New Position) | View |
2023-06-12 08:47 am Sale | 13G | UROGEN PHARMA LTD URGN | MENORA MIVTACHIM HOLDINGS LTD. | 2,919,002 12.45% | -35,697 (-1.21%) | View |
2023-02-13 10:57 am Purchase | 13G | UROGEN PHARMA LTD URGN | Stonepine Capital Management LLC | 1,304,947 5.7% | 108,039 (+9.03%) | View |
2022-12-02 11:15 am Purchase | 13G | UROGEN PHARMA LTD URGN | Stonepine Capital Management LLC | 1,196,908 5.2% | 1,196,908 (New Position) | View |
2022-07-08 4:57 pm Sale | 13G | UROGEN PHARMA LTD URGN | BlackRock Inc. BLK | 340,412 1.5% | -1,387,682 (-80.30%) | View |
2022-02-14 4:15 pm Sale | 13G | UROGEN PHARMA LTD URGN | Wildcat Capital Management LLC | 533,139 2.4% | -719,146 (-57.43%) | View |
2022-02-14 1:44 pm Sale | 13G | UROGEN PHARMA LTD URGN | CREDIT SUISSE AG | 1,085,749 4.84% | -35,322 (-3.15%) | View |
2022-02-04 09:12 am Sale | 13G | UROGEN PHARMA LTD URGN | WELLINGTON MANAGEMENT GROUP LLP | 238,008 1.06% | -1,602,629 (-87.07%) | View |
2022-02-03 4:41 pm Purchase | 13G | UROGEN PHARMA LTD URGN | BlackRock Inc. BLK | 1,728,094 7.7% | 198,603 (+12.98%) | View |
2021-02-12 4:10 pm Purchase | 13G | UROGEN PHARMA LTD URGN | Wildcat Capital Management LLC | 1,252,285 5.67% | 96,423 (+8.34%) | View |